By Michael Erman and Sriparna Roy (Reuters) -Gilead Sciences Inc on Thursday reported a higher-than-expected fourth-quarter profit driven by strong demand for its HIV and cancer...
Investing.com - Gilead (NASDAQ: GILD) reported fourth quarter EPS of $1.67, $0.17 better than the analyst estimate of $1.50. Revenue for the quarter came in at $7.4B versus the...
Gilead Sciences (GILD) reported Q4 EPS of $1.67, $0.17 better than the analyst estimate of $1.50. Revenue for the quarter came in at $7.4 billion versus the consensus estimate of...
The pharmaceutical industry is a top investment option, with the sector experiencing rapid growth in recent years. The COVID-19 pandemic has also shifted the market focus to the...
Solid earnings lift US stocks to multi-month highs despite hawkish Fed soundbitesYen slips further as markets unrattled by China flexing its military muscle over TaiwanPound edges...
S&P 500 EPS growth for Q2 is set to come in at 6.0%, the lowest level since Q4 2020 Some highly anticipated names reported last week, with big EPS misses from big...
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicine to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company’s products for HIV/AIDS patients include Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. Its COVID-19 product is Veklury. The products for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. The products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy, and Zydelig. The other products include Letairis (ambrisentan), Ranexa (ranolazine), Cayston, Jyseleca, and AmBisome (amphotericin B liposome for injection). The Company also sells and distributes generic versions of Epclusa and Harvoni in the United States. The Company is also focused on restoring immune balance with agonists targeting immune inhibitory receptors.
| Average | 86.22 (+5.93% Upside) |
| High | 111.00 |
| Low | 63.00 |
| Price | 81.39 |
| No. of Analysts | 23 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Neutral | Sell | Sell | Buy |
| Technical Indicators | Strong Buy | Buy | Strong Sell | Strong Sell | Strong Buy |
| Summary | Strong Buy | Neutral | Strong Sell | Strong Sell | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 88.31 | 88.94 | 83.20 | +3.67 | +4.34% | 96.89M | NASDAQ | |||
| 28.39 | 29.03 | 27.64 | +1.04 | +3.80% | 7.57M | NASDAQ | |||
| 108.80 | 108.82 | 106.54 | +7.37 | +7.27% | 43.60M | NASDAQ | |||
| 175.99 | 178.63 | 175.09 | +0.46 | +0.26% | 2.44M | NASDAQ | |||
| 188.27 | 196.75 | 182.61 | +6.86 | +3.78% | 214.41M | NASDAQ | |||
| 470.83 | 495.00 | 463.89 | -26.17 | -5.27% | 11.13M | NYSE | |||
| 2.77 | 2.985 | 2.71 | +0.190 | +7.36% | 3.40M | NYSE | |||
| 103.51 | 104.78 | 102.82 | -1.88 | -1.78% | 4.35M | NYSE | |||
| 112.25 | 112.37 | 110.89 | +0.43 | +0.38% | 5.00M | NYSE | |||
| 169.97 | 170.56 | 168.51 | -1.59 | -0.93% | 5.59M | NASDAQ | |||
| 41.11 | 41.15 | 39.73 | +1.14 | +2.85% | 21.29M | NASDAQ | |||
| 0.45 | 0.48 | 0.41 | +0.07 | +16.90% | 3.76M | NASDAQ | |||
| 7.72 | 8.24 | 7.45 | +0.34 | +4.61% | 105.16M | NASDAQ | |||
| 83.94 | 84.03 | 81.90 | +1.62 | +1.97% | 8.21M | NYSE | |||
| 457.19 | 460.43 | 453.92 | -5.06 | -1.09% | 2.10M | NYSE |